{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"10.8","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"PFS is defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Includes all subjects in Cohorts 1 through 5 of Phase 1 of the study who received a combination of pralatrexate and romidepsin.","id":"OG000","title":"Phase I"}],"paramType":"MEDIAN","populationDescription":"Pre-specified to report all Phase 1 data as a single Arm","reportingStatus":"POSTED","timeFrame":"Up to 1.5 years","title":"Progression Free Survival (PFS) of Subjects in Phase 1","type":"SECONDARY","unitOfMeasure":"months"}